Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro
© 2022. The Author(s)..
BACKGROUND: Triple negative breast cancer (TNBC) is a molecular subtype of breast cancer, which is a major health burden of females worldwide. Thymoquinone (TQ), a natural compound, has been found to be effective against TNBC cells, and this study identified IL17RD as a novel target of TQ in TNBC cells.
METHODS: We have performed chromatin immunoprecipitation Sequence (ChIP-Seq) by MBD1 (methyl-CpG binding domain protein 1) antibody to identify genome-wide methylated sites affected by TQ. ChIP-seq identified 136 genes, including the tumor suppressor IL17RD, as a novel target of TQ, which is epigenetically upregulated by TQ in TNBC cell lines BT-549 and MDA-MB-231. The IL17RD expression and survival outcomes were studied by Kaplan-Meier analysis.
RESULTS: TQ treatment inhibited the growth, migration, and invasion of TNBC cells with or without IL17RD overexpression or knockdown, while the combination of IL17RD overexpression and TQ treatment were the most effective against TNBC cells. Moreover, higher expression of IL17RD is associated with longer survival in TNBC patients, indicating potential therapeutic roles of TQ and IL17RD against TNBC.
CONCLUSIONS: Our data suggest that IL17RD might be epigenetically upregulated in TNBC cell lines by TQ, and this might be one of the mechanisms by which TQ exerts its anticancer and antimetastatic effects on TNBC cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
BMC cancer - 22(2022), 1 vom: 27. Juni, Seite 707 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Md Asaduzzaman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Benzoquinones |
|---|
| Anmerkungen: |
Date Completed 29.06.2022 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-022-09782-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342822322 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342822322 | ||
| 003 | DE-627 | ||
| 005 | 20231226015013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-022-09782-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342822322 | ||
| 035 | |a (NLM)35761256 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khan, Md Asaduzzaman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Triple negative breast cancer (TNBC) is a molecular subtype of breast cancer, which is a major health burden of females worldwide. Thymoquinone (TQ), a natural compound, has been found to be effective against TNBC cells, and this study identified IL17RD as a novel target of TQ in TNBC cells | ||
| 520 | |a METHODS: We have performed chromatin immunoprecipitation Sequence (ChIP-Seq) by MBD1 (methyl-CpG binding domain protein 1) antibody to identify genome-wide methylated sites affected by TQ. ChIP-seq identified 136 genes, including the tumor suppressor IL17RD, as a novel target of TQ, which is epigenetically upregulated by TQ in TNBC cell lines BT-549 and MDA-MB-231. The IL17RD expression and survival outcomes were studied by Kaplan-Meier analysis | ||
| 520 | |a RESULTS: TQ treatment inhibited the growth, migration, and invasion of TNBC cells with or without IL17RD overexpression or knockdown, while the combination of IL17RD overexpression and TQ treatment were the most effective against TNBC cells. Moreover, higher expression of IL17RD is associated with longer survival in TNBC patients, indicating potential therapeutic roles of TQ and IL17RD against TNBC | ||
| 520 | |a CONCLUSIONS: Our data suggest that IL17RD might be epigenetically upregulated in TNBC cell lines by TQ, and this might be one of the mechanisms by which TQ exerts its anticancer and antimetastatic effects on TNBC cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ChIP-Seq | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a IL17RD | |
| 650 | 4 | |a Mehtylation | |
| 650 | 4 | |a Thymoquinone | |
| 650 | 4 | |a Triple negative breast cancer | |
| 650 | 7 | |a Benzoquinones |2 NLM | |
| 650 | 7 | |a IL17RD protein, human |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin |2 NLM | |
| 650 | 7 | |a thymoquinone |2 NLM | |
| 650 | 7 | |a O60IE26NUF |2 NLM | |
| 700 | 1 | |a Zheng, Meiling |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Jiewen |e verfasserin |4 aut | |
| 700 | 1 | |a Tania, Mousumi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Junjiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 22(2022), 1 vom: 27. Juni, Seite 707 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:27 |g month:06 |g pages:707 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-022-09782-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |b 27 |c 06 |h 707 | ||